296. 胆道閉鎖症 Biliary atresia Clinical trials / Disease details
臨床試験数 : 71 / 薬物数 : 70 - (DrugBank : 39) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 60
Showing 1 to 10 of 71 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05426733 (ClinicalTrials.gov) | July 5, 2022 | 13/6/2022 | An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children Wi ... | An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia (BOLD-EXT) An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Chi ... | Biliary Atresia | Drug: Odevixibat | Albireo | NULL | Enrolling by invitation | N/A | N/A | All | 180 | Phase 3 | United States;Canada;Italy;Malaysia;New Zealand;Poland;Spain |
| 2 | NCT05521152 (ClinicalTrials.gov) | May 1, 2022 | 28/8/2022 | Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenteros ... | Prophylactic Use of Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy Operation for Biliary Atresia: Double Blinded Randomized Controlled Trial Prophylactic Use of Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoin ... | Anesthesia;Pediatrics;Biliary Atresia | Drug: Norepinephrine Bitartrate;Drug: Placebo | Kasr El Aini Hospital | NULL | Recruiting | 1 Month | 4 Months | All | 40 | Phase 3 | Egypt |
| 3 | ChiCTR2200059705 | 2022-05-01 | 2022-05-08 | Machine Learning Based on Sonographic Gallbladder Images in Prenatal Diagnosis of Biliary Atresia | Machine Learning Based on Sonographic Gallbladder Images in Prenatal Diagnosis of Biliary Atresia | Biliary atresia | Gold Standard:Surgical exploration, puncture biopsy, intraoperative cholangiography, or percutaneous cholecystography ;Index test:Intelligent prenatally diagnostic system based on sonographic gallbladder images; GoldStandard:Surgical exploration, puncture biopsy, intraoperative cholangiography, or percutaneous ... | Shengjing Hospital of China Medical University | NULL | Pending | Female | Target condition:2000;Difficult condition:0 | China | |||
| 4 | EUCTR2014-004693-42-FR (EUCTR) | 25/04/2022 | 07/01/2022 | A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension. A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multip ... | A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study, with an Optional Open-Label Extension to Assess the Safety, Tolerability, and Pharmacokinetics of Obeticholic Acid in Pediatric Subjects with Biliary Atresia - ObetiCholic Acid in Pediatric Subjects with BiliaRy AtrEsia (CARE) A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study, with an Optional Open-Labe ... | Biliary atresia MedDRA version: 20.0;Level: LLT;Classification code 10004653;Term: Biliary atresia;System Organ Class: 100000004850 MedDRA version: 20.1;Classification code 10004654;Term: Biliary atresia, congenital;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Biliary atresia MedDRA version: 20.0;Level: LLT;Classification code 10004653;Term: Biliary atresia;S ... | Product Name: OCA 1.5mg Product Code: OCA INN or Proposed INN: obeticholic acid Trade Name: Ocaliva Product Name: OCA 5mg Product Code: OCA INN or Proposed INN: obeticholic acid Product Name: OCA 0.1 mg Product Code: OCA INN or Proposed INN: obeticholic acid Other descriptive name: OBETICHOLIC ACID Product Name: OCA1.5mg Product Code: OCA INN or Proposed INN: obeticholic acid Trade Name: Ocaliva Produ ... | Intercept Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 32 | Phase 2 | France;Finland;Poland;Belgium;Netherlands;Germany;United Kingdom | ||
| 5 | ChiCTR2200055459 | 2022-02-01 | 2022-01-10 | Establishment of a diagnostic model of biliary atresia ultrasound combined with MMP-7: a multicenter diagnostic accuracy study Establishment of a diagnostic model of biliary atresiaultrasound combined with MMP-7: a multicenter ... | Establishment of a diagnostic model of biliary atresia ultrasound combined with MMP-7: a multicenter diagnostic accuracy study Establishment of a diagnostic model of biliary atresiaultrasound combined with MMP-7: a multicenter ... | Biliary atresia | Gold Standard:Biliary tract exploration and liver pathology.;Index test:MMP-7, ultrasound, MMP-7 and ultrasound combined diagnostic model.; GoldStandard:Biliary tract exploration and liver pathology.;Index test:MMP-7, ultrasound, MMP-7 and ... | Pediatric Hospital Affiliated to Fudan University | NULL | Recruiting | Both | Target condition:150;Difficult condition:150 | China | |||
| 6 | ChiCTR2100053800 | 2021-12-13 | 2021-11-29 | Multimodal Magnetic Resonance Imaging for Evaluating the Developmental State of Bile Ducts and the Degree of Hepatic Fibrosis in Children with Biliary Atresia Multimodal Magnetic Resonance Imaging for Evaluating the Developmental State of Bile Ducts and the D ... | Multimodal Magnetic Resonance Imaging for Evaluating the Developmental State of Bile Ducts and the Degree of Hepatic Fibrosis in Children with Biliary Atresia Multimodal Magnetic Resonance Imaging for Evaluating the Developmental State of Bile Ducts and the D ... | Biliary Atresia | Gold Standard:Intraoperative cholangiography is often considered the diagnostic gold standard for biliary atresia. Blood biochemical examination is used as a reference standard for evaluating liver fibrosis.;Index test:Multimodal Magnetic Resonance Imaging; GoldStandard:Intraoperative cholangiography is often considered the diagnostic goldstandard for bili ... | Children's Hospital of Chongqing Medical University | NULL | Recruiting | Both | Target condition:100;Difficult condition:0 | China | |||
| 7 | NCT05072626 (ClinicalTrials.gov) | October 11, 2021 | 13/9/2021 | High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia | Study on High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia After Kasai Portoenterostomy Study on High Medium-chain Triglyceride Nutritional Support in Infants With Biliary AtresiaAfter Kas ... | Biliary Atresia;Infant;Nutrition Support;Medium-chain Triglyceride | Combination Product: high MCT formula;Dietary Supplement: MCT powder | Children's Hospital of Fudan University | NULL | Recruiting | N/A | 3 Months | All | 300 | N/A | China |
| 8 | ChiCTR2100050992 | 2021-10-08 | 2021-09-10 | Treatment of biliary atresia and prevention of postoperative cholangitis with folic acid: Multicenter clinical study on drug efficacy Treatment of biliary atresiaand prevention of postoperative cholangitis with folic acid: Multicenter ... | Therapeutic and preventive effect of Folic acid on billiary atresia and postoperative cholangitis | biliary atresia | control group:Conventional therapy;experimental group:Conventional therapy+Folic acid; | Guangzhou Women and Children Medical Center | NULL | Recruiting | 0 | 2 | Both | control group:150;experimental group:150; | China | |
| 9 | NCT04524390 (ClinicalTrials.gov) | July 8, 2021 | 20/8/2020 | Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai | Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Biliary Atresia After Hepatoportoenterostomy Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Ma ... | Biliary Atresia | Drug: Maralixibat;Other: Placebo | Mirum Pharmaceuticals, Inc. | NULL | Recruiting | 21 Days | 111 Days | All | 72 | Phase 2 | United States;China;Germany;Hong Kong;Poland;Singapore;Taiwan;United Kingdom;Vietnam |
| 10 | ChiCTR2100046985 | 2021-06-01 | 2021-06-06 | A clinical study of biliary atresia treatment with Belimumab | Immune pathogenesis and treatment of biliary atresia | biliary atresia | Control Group:Conventional therapy;Experimental group:Belimumab; | Guangzhou Women and Children Medical Center | NULL | Recruiting | 0.1 | 0.3 | Both | Control Group:6;Experimental group:6; | Phase 4 | China |